Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.56 |
| ▸ | ERBB2 | P04626 | 13/20 | 0.53 |
| ▸ | NQO2 | P16083 | 1/20 | 0.50 |
| ▸ | FECH | P22830 | 1/20 | 0.50 |
| ▸ | MYH14 | Q7Z406 | 1/20 | 0.50 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29935838 | 1.00 | EGFR (0.56) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL26697709 | 0.91 | ERBB2 (0.57) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL31257514 | 0.91 | ERBB2 (0.51) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL26005290 | 0.90 | ERBB2 (0.52) | EGFRERBB2 | |
| SCHEMBL31541191 | 0.90 | ERBB2 (0.52) | EGFRERBB2 | |
| SCHEMBL26008871 | 0.90 | ERBB2 (0.52) | EGFRERBB2 | |
| SCHEMBL30576108 | 0.90 | ERBB2 (0.52) | EGFRERBB2 | |
| SCHEMBL30575910 | 0.90 | ERBB2 (0.52) | EGFRERBB2 | |
| SCHEMBL26895471 | 0.90 | EGFR (0.59) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL25432391 | 0.86 | ERBB2 (0.58) | EGFRERBB2NQO2FECHMYH14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037346-B2 | Amino-substituted heteroaryls for treating cancers with EGFR mutations | NUVALENT, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037346-B2 | Amino-substituted heteroaryls for treating cancers with EGFR mutations | NUVALENT, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| EP-4323356-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | Nuvalent, Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| WO-2022221227-A9 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | NUVALENT, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023154124-A1 | ACYLATED HETEROCYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037346-B2 | Amino-substituted heteroaryls for treating cancers with EGFR mutations | EGFR, ERBB2, ERBB3 | EGFR 1/4885ERBB2 2/4885NQO2 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.